Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2273-2281

  Du, Yuefeng ^a   Long, Qingzhi ^a   Shi, Ying ^b   Liu, Xiaogang ^a   Li, Xudong ^a   Zeng, Jin ^a   Gong, Yongguang ^a   Li, Lei ^a   Wang, Xinyang ^a   He, Dalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

IGF binding protein 3; Mammalian target of rapamycin; Prostate cancer

Indexed keywords

ADJUVANT; INTERLEUKIN 24; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; S6 KINASE; SOMATOMEDIN BINDING PROTEIN 3; IGFBP3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; MCL1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ACTIVITY; DOWN REGULATION; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; HEK293 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTERLEUKINS; MALE; MICE, NUDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84941966239     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4201     Document Type: Article

References (29)

1. Gill ZP, Perks CM, Newcomb PV and Holly JM: Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272: 25602-25607, 1997.
2. Nakamura M, Takakura M, Fujii R, Maida Y, Bono Y, Mizumoto Y, Zhang X, Kiyono T and Kyo S: The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth. Cancer Lett 336: 68-75, 2013.
3. Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T and Koide N: Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 5: 9, 2005.
4. Baxter RC, Butt AJ, Schedlich LJ and Martin JL: Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res 10 (10 Suppl A): S10-S11, 2000.
5. Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS and Alman B: Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16: 126-136, 2009.
6. Butt AJ and Williams AC: IGFBP-3 and apoptosis - a license to kill? Apoptosis 6: 199-205, 2001.
7. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM and Paraskeva C: Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 60: 22-27, 2000.
8. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D and Holly JM: IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 88: 336-341, 2000.
9. Collard TJ, Guy M, Butt AJ, Perks CM, Holly JM, Paraskeva C and Williams AC: Transcriptional upregulation of the insulinlike growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenomaderived epithelial cells. Carcinogenesis 24: 393-401, 2003.
10. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D, et al: Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 20: 7051-7063, 2001.
11. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S and Grimm EA: Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 20: 1069-1074, 2002.
12. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, et al: MDA-7/IL-24 is a unique cytokine - tumor suppressor in the IL-10 family. Int Immunopharmacol 4: 649-667, 2004.
13. Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, et al: The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 128: 375-384, 2010.
14. Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A and Neamati N: Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Lett 335: 421-430, 2013.
15. Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J and Fisher PB: Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol 215: 827-836, 2008.
16. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ and Grimm EA: IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res 21: 44-56, 2010.
17. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S and Fisher PB: MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 14: 35-51, 2003.
18. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, et al: Melanoma differentiation associated gene-7 (mda-7): A novel anti-tumor gene for cancer gene therapy. Mol Med 7: 271-282, 2001.
19. Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, Vorburger SA, Pataer A, Swisher SG, Ramesh R, et al: mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: Correlation with expression of bcl-2 family members. Cancer Gene Ther 13: 490-502, 2006.
20. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC and Fisher PB: Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773, 2003.
21. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
22. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51, 2010.
23. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
24. Cusack JC Jr: Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 10: 852-862, 2003.
25. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D and Zoli W: Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 6: 43, 2008.
26. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, et al: mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105: 10853-10858, 2008.
27. Chan S: Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91: 1420-1424, 2004.
28. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 96 (Suppl): R11-R15, 2007.
29. Adams JM: Ways of dying: Multiple pathways to apoptosis. Genes Dev 17: 2481-2495, 2003.